PAHC

SEC source: 0001104659-26-006986 · tm264120-1_4seq1.xml · derivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,911,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-006986 · tm264120-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 45,445

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-006986 · tm264120-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 15,445

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.175 to $41.01. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-005914 · tm263655-2_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 16,680

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.62 to $42.77.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-005914 · tm263655-2_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 17.963

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.53.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-005914 · tm263655-2_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 29,838

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.11 to $42.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 44,525

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · derivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,941,034

Underlying: Class A Common Stock · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 47,457

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.125 to $41.15.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 47,850

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.025 to $40.985.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 51,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-004189 · tm263276-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 31,108

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.09 to $40.51. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-003467 · tm262975-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,659

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-002221 · tm262516-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,872

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $40.26. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-121213 · tm2533388-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 39,200

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.095 to $41.38.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-121213 · tm2533388-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 42,195

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.035 to $41.025. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-119982 · tm2533142-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 44,952

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.34.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-119982 · tm2533142-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 46,240

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.195. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 49,760

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.73 to $41.775.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 50,128

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.73 to $41.72.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,961,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 53,280

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.30 to $41.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 and 6.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 56,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-117716 · tm2532519-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 26,800

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.38 to $41.895.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-117716 · tm2532519-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 30,320

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.12 to $43.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-116504 · tm2532256-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 33,840

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.79 to $44.37.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-116504 · tm2532256-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 39,120

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.195. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-115420 · tm2531940-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 46,160

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-115420 · tm2531940-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 46,221

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.29 to $42.25. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 49,680

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 49,700

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.27 to $44.26.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 54,960

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.24 to $44.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 5.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,991,034

Underlying: Class A Common Stock · 55,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 60,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 5,240

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $45.465.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 6,894

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.78.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 14,041

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.95 to $45.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 and 6.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,046,034

Underlying: Class A Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 35,577

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,577

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.355 to $46.36.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,897

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.33 to $46.32.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 40,670

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.26.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 54,756

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.31 to $44.28.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 58,880

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.61 to $43.195. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6 and 7.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 62,400

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $42.14.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 63,372

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $41.535.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · derivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,061,034

Underlying: Class A Common Stock · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 65,920

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.555 to $43.705.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 66,444

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 69,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.